The geography of DEA opioid enforcement reflects the geography of the opioid crisis itself, which was never distributed uniformly across the country.
The states that experienced the earliest and most severe waves of prescription opioid abuse were the states that generated the first major DEA enforcement actions, and those states continue to be disproportionate enforcement priorities even as the crisis has evolved and spread. The pattern of enforcement concentration in specific states reflects the overlap of several factors: high rates of opioid prescribing, inadequate prescription monitoring infrastructure during the early years of the crisis, concentrations of pill mill activity that attracted DEA investigative resources, and the political and public health attention that high overdose rates generated.
Florida
Florida was the epicenter of the pill mill crisis during the late 2000s and early 2010s. The state’s combination of permissive pain clinic regulations, no prescription drug monitoring program until 2009, and a population that included both a large number of chronic pain patients and a well-organized network of individuals who traveled from out of state to obtain opioid prescriptions created conditions in which pill mills proliferated at a scale unmatched elsewhere in the country.
At the peak of Florida’s pill mill crisis, the state accounted for approximately ninety percent of all oxycodone distributed by physicians in the United States. The DEA’s response included major enforcement actions against clinics in Broward, Palm Beach, and Hillsborough counties that produced hundreds of criminal prosecutions and the closure of hundreds of pain clinics. Florida subsequently enacted prescription drug monitoring requirements, imposed restrictions on physician dispensing, and established regulations for pain management clinics that addressed the most egregious operational characteristics of the pill mill model.
Florida remains a state of significant DEA enforcement activity, though the focus has shifted from the large-scale pill mill operations to individual practitioners whose prescribing patterns continue to appear as outliers in the PDMP data.
West Virginia
West Virginia has consistently ranked among the states with the highest opioid overdose death rates in the country, and its relatively small population means that the absolute number of opioid-related deaths has produced a per-capita rate that has drawn sustained federal attention. The state’s geography, its economic characteristics, and the concentration of population in areas with limited healthcare access created conditions in which opioid prescribing became deeply embedded in the management of chronic pain associated with physical labor industries.
The DEA’s enforcement activity in West Virginia has included major investigations of distributors who supplied pharmacies in the state with quantities of opioids that bore no relationship to legitimate patient need. The congressional investigations that produced the Drug Enforcement Administration’s loss of key enforcement tools over a period between approximately 2014 and 2016 were substantially driven by reporting on DEA enforcement in West Virginia and the resistance that enforcement encountered from the pharmaceutical distribution industry and its congressional allies.
Need Help With Your Case?
Don't face criminal charges alone. Our experienced defense attorneys are ready to fight for your rights and freedom.
- 100% Confidential
- Response Within 1 Hour
- No Obligation Consultation
Or call us directly:
(212) 300-5196Kentucky, Ohio, and Tennessee
The Appalachian states that border West Virginia, principally Kentucky, Ohio, and Tennessee, experienced the opioid crisis with similar intensity and have been consistent DEA enforcement priorities as a result. Kentucky was among the states where prescription opioid abuse transitioned earliest to heroin use as prescribing restrictions reduced the availability of pharmaceutical opioids, and the DEA’s enforcement in Kentucky has addressed both the prescribing side and the trafficking side of that transition.
Ohio, and specifically the cities of Columbus, Cincinnati, and Dayton, became focal points of fentanyl-related overdose deaths as illicitly manufactured fentanyl displaced pharmaceutical opioids and heroin in the illicit drug supply. The DEA’s Ohio enforcement has concentrated heavily on the fentanyl trafficking organizations responsible for the supply chain that produced those deaths, alongside continued investigation of the prescribing and dispensing practices that preceded the fentanyl transition.
New England
The opioid crisis spread to New England with particular severity, affecting states including New Hampshire, Maine, Massachusetts, and Vermont that had not historically been associated with the drug trafficking patterns that drove the crisis in Appalachian states. The transition from prescription opioid abuse to heroin and fentanyl in New England was documented with particular rigor, and the DEA’s enforcement activity in the region has reflected both the trafficking side of the crisis and the prescribing and dispensing practices that contributed to the population of opioid-dependent individuals in these states.
Massachusetts, with its concentration of healthcare institutions and its sophisticated regulatory environment, has been a state in which healthcare practitioner enforcement has been prominent. The prosecutions of Massachusetts practitioners for opioid prescribing outside the usual course of professional practice have been among the most closely watched in the country, producing case law that has affected the defense of practitioners in other jurisdictions.
Todd Spodek
Lead Attorney & Founder
Featured on Netflix's "Inventing Anna," Todd Spodek brings decades of high-stakes criminal defense experience. His aggressive approach has secured dismissals and acquittals in cases others deemed unwinnable.
The geographic concentration of DEA enforcement reflects where the data showed the highest rates of diversion and the most severe public health consequences. It does not reflect the limits of the DEA’s enforcement authority, which is nationwide. A practitioner in a state not historically associated with opioid enforcement activity who generates a prescribing pattern that appears anomalous in the PDMP data is a practitioner whose geographic location provides no protection.
Federal agents execute a search warrant at your medical practice, seizing patient records and prescription logs.
Can they take patient records without patient consent?
A valid federal search warrant overrides HIPAA privacy protections. However, the warrant must be properly scoped. An attorney can challenge overly broad warrants and move to suppress improperly seized evidence.
This is general information only. Contact us for advice specific to your situation.
The National Expansion
While the states described above have been the most prominent DEA opioid enforcement targets, the enforcement has expanded to every state as the crisis has spread and as the DEA’s data analytics capabilities have improved. The practitioner who assumes that DEA opioid enforcement is a problem for states other than their own is a practitioner who has not kept pace with the enforcement environment.
The DEA’s current enforcement priorities reflect a nationwide commitment to addressing opioid diversion across the full range of the supply chain, in every state, against practitioners in every specialty who hold DEA registrations and whose prescribing patterns generate the data flags that initiate investigations. Geographic location is not a defense. Clinical record-keeping is.
